You are here: Industry Insights > erenumab

News List

Novartis cedes US operations for migraine drug Aimovig to Amgen firstwordpharma
June 17, 2021
Novartis will transfer previously shared US business operations for the anti-CGRP migraine therapy Aimovig (erenumab) to its partner Amgen, the companies confirmed to FirstWord Pharma on Wednesday.
Erenumab migraine drug fails to meet NICE recommendation standards europeanpharmaceuticalreview
September 27, 2019
NICE has announced that it will not be recommending erenumab, an injectable migraine treatment, due to issues with cost and its long-term effectiveness.
Novartis to globally co-commercialise Amgen’s migraine drug europeanpharmaceuticalreview
May 07, 2019
Novartis has expanded their commercialisation agreement with Amgen for AMG 334 (erenumab), which is being investigated for the prevention of migraine…
Aimovig approved by EU for migraine prevention europeanpharmaceuticalreview
April 19, 2019
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15…
Amgen, Novartis’ migraine therapy impresses again pharmatimes
July 16, 2018
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in epis worldpharmanews
January 23, 2018
The study met its primary endpoint, with significantly more patients taking erenumab experiencing at least a 50% reduction from baseline in their monthly migraine days as compared to placebo.